This inventor holds 1 USPTO granted patent. Top assignee: Xintela Ab. Active years: 2016.
Company Filing History:
Years Active: 2016
Title: Evy Lundgren-Åkerlund: Innovator in Monoclonal Antibody Research
Introduction
Evy Lundgren-Åkerlund is a prominent inventor based in Bjarred, Sweden. She has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. Her work focuses on innovative solutions for medical applications, showcasing her dedication to advancing scientific knowledge and healthcare.
Latest Patents
Evy Lundgren-Åkerlund holds a patent for a monoclonal antibody capable of binding integrin alpha 10 beta 1. This invention provides a monoclonal antibody or a fragment thereof that binds to the extracellular I-domain of integrin alpha10beta1. The patent also includes a hybridoma cell line deposited at the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH under the accession number DSM ACC2583. The methods and uses of this antibody are aimed at identifying and selecting cells of a chondrogenic nature for treatment purposes. This includes the identification and isolation of chondrocytes, mesenchymal progenitor cells, and embryonic stem cells for tissue engineering of cartilage. Additionally, it offers diagnostic and therapeutic tools for studying the biological role and structural/functional relationships of integrin alpha10beta1 with its various extracellular matrix ligands.
Career Highlights
Evy Lundgren-Åkerlund is associated with Xintela AB, a company that focuses on developing innovative therapies based on stem cell technology. Her work at Xintela AB emphasizes the importance of her research in the context of regenerative medicine and tissue engineering. With her expertise, she has contributed to the advancement of therapeutic options for various medical conditions.
Collaborations
Due to space constraints, the collaborations section has been omitted.
Conclusion
Evy Lundgren-Åkerlund is a trailblazer in the field of monoclonal antibody research, with her innovative patent contributing to advancements in medical science. Her work continues to inspire future developments in biotechnology and regenerative medicine.